|
WINNIPEG, Manitoba (August 17, 2007) - Miraculins Inc. (TSX-V: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, today announces an amendment to the previously announced non-brokered private placement offering.
Read More
|
|
Miraculins Inc. (TSX-V: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, today announces a non-brokered private placement offering.
Read More
|
|
Miraculins Inc., a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce further results that indicate its prostate cancer test could be used as a tumor grading test.
Read More
|
|
Miraculins Inc., a biotechnology company engaged in the discovery and development of products for select cancers, announces the re-election of Dr. Albert Friesen, Dr. Phiet Bui, Dr. Jim Charlton, Mr. Peter de Visser and Mr. Ted Paetkau to the Company's Board of Directors at today's Annual General and Special Meeting of Shareholders.
Read More
|
|
Miraculins Inc. (TSX:V:MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products is pleased to announce the final results from its PCSC04 study.
Read More
|
|
|